Curzion Pharmaceuticals
San Diego
About Curzion Pharmaceuticals
Curzion Pharmaceuticals is a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Funding stage: M&A
- Last round: Series Unknown (Jan 2019)
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/curzion-pharmaceuticals-2443724 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.